CORRECTION OF CYTOSTATIC-INDUCED IMMUNOSUPRESSION WITH STAPHYLOCOCCAL VACCINE IN MICE


Cite item

Full Text

Abstract

Studies aimed on evaluation of possibility for correction of cyclophosphan-induced immunosupression in BALB/c mice by using acellular staphylococcal vaccine «Staphylovac» (SV). Cyclophosphan (CP) administered to mice four times with 24 hours intervals decreased levels of T-, B-, T-regulatory (T-reg CD4/CD25/Foxp3) lymphocytes, increased quantity of cells expressing early activation marker D25 (assessment after 4 hours). Administration of SV alongside with cytostatic does not influenced significantly on characteristics of CP-induced immunosupression at the moment of its assessment. Twenty four hours after administration of CP or SV with CP level of cells expressing CD3 and MHC I continued to decrease as compared with control. Compared with administration of CP only or with control group, SV administered alongside with CP increased expression of MHC II on 38and 1.8-fold respectively. Levels of CD4, CD25, CD8, and CD19 cells in these groups were already closer to control values that points to the beginning of restoration of some disturbances in mechanisms of immunoregulation. Five days after administration of CP or CP+SV levels of CD3, MHC I, and CD8 lymphocytes significantly increased, although were lower than in the control group in 3.3and 2.3-fold (CD3), 12and 4-fold (MHC I), and in 2.8and 1.8-fold (CD8) respectively. Levels of NK, NKT were higher as compared to control. CP continued to decrease levels of CD4 and CD19 cells and simultaneously increased level of T-regulatory cells, which play key role in suppression of immune response. Administration of SV during CP course corrected levels of cells expressing these markers. It was established that under the influence of SV, cytotoxic potential of NK cells and proliferative activity of lymphocytes were restored.

Full Text

КОРРЕКЦИЯ ИНДУЦИРОВАННОЙ ЦИТОСТАТИКОМ ИММУНОСУПРЕССИИ У МЫШЕЙ С ПОМОЩЬЮ СТАФИЛОКОККОВОЙ ВАКЦИНЫ
×

About the authors

N. K Akhmatova

Mechnikov Research Institute of Vaccines and Sera; Blokhin Russian Oncologic Scientific Center, Moscow, Russia

O. M Kuzmenko

Mechnikov Research Institute of Vaccines and Sera; Blokhin Russian Oncologic Scientific Center, Moscow, Russia

I. M Gruber

Mechnikov Research Institute of Vaccines and Sera; Blokhin Russian Oncologic Scientific Center, Moscow, Russia

F. V Donenko

Mechnikov Research Institute of Vaccines and Sera; Blokhin Russian Oncologic Scientific Center, Moscow, Russia

References

  1. Ахматова Н.К., Киселевский М.В., Курбатова Е.А. и др. Иммуномодулятор Иммуновак-ВП-4 уменьшает иммуносупрессию и усиливает цитотоксическую активность цитостатика цисплатина. Журн. микробиол. 2005, 2: 44—48.
  2. Гольдберг Е.Д., Дыгай А.М., Шерстобоев Е.Ю. Механизмы локальной регуляции кроветворения. Томск, STT, 2000.
  3. Ефремова В.Н., Егорова Н.Б., Масюкова С.А. Бесклеточная антистафилококковая вакцина для лечения хронической стафилококковой инфекции. Патент № 21228620, 08.12.98.
  4. Кокорев О.В., Чердынцева Н.В, Зюзикова О.В. Способ повышения противоопухолевой и антиметастатической активности циклофосфана в эксперименте. ГУ НИИ онкологии СО РАМН. Патент РФ RU 2270682, 2004. www. NTPO.com.
  5. Лазарева Д.Н., Сакаева Д.Д. Клиническая фармакология в онкологии. МИА, 2007.
  6. Лебедев К.А., Понякина И.Д. Иммунная недостаточность. М., Мед книга, Н.Новгород, Изд. НГМА, 2003.
  7. Муфазалова Н.А., Трещалин И.Д., Трещалина Е.М. и др. Эффект Т-активина и витамина Е на токсичность и противоопухолевую активность циклофосфамида. Бюлл. экспер. биол. мед. 2004, 137 (1): 37—39.
  8. Семенов Б.Ф. Терапевтические вакцины. Росс. мед. вести. 2000, 5 (3): 26—32.
  9. Хаитов Р.М., Пинегин Б.В. Иммуномодуляторы: механизм действия и клиническое применение. Иммунология. 2003, 4: 196—203.
  10. Шубина И.Ж., Блюменберг А.Г., Волков С.М. и др. Адоптивная иммунотерапия злокачественных новообразований. Вестн. РАМН. 2007, 11: 9—15.
  11. Alexon H.W., Oberg G., Askmark H. Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell trans- plantation in CIDP. J. Neurosurg. Psychiatry. 2008, 79 (5): 612—614.
  12. Manna S.K, Aggarwal B.B. Differential reguirement for p56lck in HIV-tat versus TNF-induced cellular responces: effects on NF-kappa B, activator protein-1, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 2000, 164: 5156—5166.
  13. Matsuoka H., Fujimura T., Mori et al. Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmac. 2007, 7 (11): 1422—1432.
  14. Papewal is C., Wuttke M., Jacobs B. et al. D end r itic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma. Horm Metab. Res. 2008, 40 (2): 108—116.
  15. Park K.R., Lee J.H., Choi C. et al. Suppression of interleukin-2 gene expression by isoeugenol is mediated through down-regulation of NF-AT and NF-kappaB. Int Immunopharmac. 2007, 7 (9): 1251—1258.
  16. Weber K.S., Miller M.J., Allen P.M. Th17 cells exhibit a distinct calcium profile from Th1 and Th2 cells and have Th1-like motility and NF-AT nuclear localization. J. Immunol. 2008, 180 (3): 1442—1450.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2009 Akhmatova N.K., Kuzmenko O.M., Gruber I.M., Donenko F.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies